

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/08	A1	(11) International Publication Number: WO 95/22982 (43) International Publication Date: 31 August 1995 (31.08.95)
<p>(21) International Application Number: PCT/KR94/00125</p> <p>(22) International Filing Date: 16 September 1994 (16.09.94)</p> <p>(30) Priority Data: 1994/3490 25 February 1994 (25.02.94) KR</p> <p>(71) Applicant (for all designated States except US): CHONG KUN DANG CORP. [KR/KR]; 410, Shindorim-dong, Guro-gu, Seoul 152-070 (KR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KIM, Jung, Woo [KR/KR]; 925-7, Hwagog 1-dong, Kangseo-gu, Seoul 157-011 (KR). SHIN, Hee, Jong [KR/KR]; Block 1404-101, Joong 2-dong 14-1, Wonmi-gu, Bucheon, Kyeonggi-do 421-110 (KR). PARK, Joon, Kyu [KR/KR]; 629-34, Shimgog bon 1-dong, Sosa-gu, Bucheon, Kyeonggi-do 422-011 (KR). MIN, Kyeong, Bok [KR/KR]; 1626-23, Pongchun-dong 7, Kwanak-gu, Seoul 151-050 (KR).</p> <p>(74) Agents: CHOI, Kyu, Pal et al.; 824-20, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR).</p>		<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GH, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SI).</p> <p>Published With international search report. With amended claims.</p>

(54) Title: CYCLOSPORIN-CONTAINING POWDER COMPOSITION

(57) Abstract

The present invention relates to a cyclosporin-containing powder composition which comprises cyclosporin, a non-ionic hydrophilic surfactant and a porous carrier. In addition, the present invention relates to a method for preparing the cyclosporin-containing powder composition which comprises dissolving cyclosporin and a non-ionic hydrophilic surfactant in an organic solvent, adding a porous carrier to the resulting solution and then evaporating the organic solvent from the mixture. The powder composition of the present invention is stable and does not require a special manufacturing technique when it is formulated. In addition, since the powder composition of the present invention does not contain an organic solvent, the necessity of a special package is excluded. Furthermore, the composition of the present invention provides an improved bioavailability which results in decrease of a single dosage, and therefore, can contribute to the alleviation of the side effects associated with cyclosporin.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CYCLOSPORIN-CONTAINING POWDER COMPOSITION

TECHNICAL FIELD

5

The present invention relates to a cyclosporin-containing powder composition. More particularly, the present invention relates to a cyclosporin-containing powder composition having an improved stability and an increased bioavailability, which contains cyclosporin, a non-ionic hydrophilic surfactant and a porous carrier. In addition, the present invention relates to a process for preparing the cyclosporin-containing powder composition.

15

BACKGROUND ART

Cyclosporin is a peptide compound having a unique structure consisting of 11 poly-N-methylated amino acids and has been known as having useful pharmacological activities, particularly immunosuppressive activity, antiinflammatory activity and the like. Cyclosporin compound which was first isolated from the natural product is cyclosporin as a spontaneous fungi metabolite, which is generally known as cyclosporin A and is the most widely used cyclosporin compound at the present time. Since cyclosporin A is first discovered, numerous cyclosporin compounds present in the natural world have been isolated and identified. At the present time they are prepared on industrial scale by a synthetic or semi-synthetic method or by a modified culture method.

Cyclosporin A has been recognized as having a very great value as an immunosuppressive agent in the clinical field. The effectiveness of cyclosporin A as the immunosuppressive agent is demonstrated particularly in the

field of organ transplantation, for example, transplantation of heart, lung, liver, kidney, pancreas, bone marrow, skin and cornea tissues. In addition, cyclosporin A is very useful for the treatment of autoimmune diseases and inflammatory conditions, particularly arthritis, for example, rheumatoid arthritis, chronic arthritis, progressive arthritis and arthritic malformation, and inflammatory conditions caused by autoimmune components such as rheumatic diseases.

However, in spite of the great effectiveness of cyclosporin in the field of organ transplantation and treatment of autoimmune diseases the clinical use of cyclosporin is very restricted because cyclosporin is very difficult to provide an effective and convenient administration method and has undesirable side effects such as serious nephrotoxicity. In addition, since cyclosporin is highly hydrophobic, it cannot be expected that the formulation prepared by a conventional method will provide an effective therapeutic effect.

In order to solve the above-mentioned problems related to cyclosporin U.S. Patent No. 4,388,307 suggests a method for preparing a liquid formulation for internal use by mixing cyclosporin with Labrafil or Miglyol, ethanol and corn oil. However, such a liquid formulation should be administered as a dilution in potable water and is very difficult to provide the desired precise dosage for oral administration. Such problems involved in the liquid formulation could be solved by using a soft gelatin capsule formulation.

However, the cyclosporin soft gelatin capsule preparation has also a problem that ethanol as a solvent for cyclosporin should be used in a large amount in order to keep cyclosporin in the state of solution. Specifically, when ethanol, which has a low boiling point, is evaporated

from the capsule preparation, cyclosporin is precipitated and the precipitated cyclosporin is substantially not absorbed in the living body. Accordingly, the reduced ethanol content due to evaporation during storage has a significant influence upon the effect of cyclosporin preparation. In order to avoid such problem the soft gelatin capsule should be packed in the closed space, or wrapped in a special packing material such as a sealing film foam package or an aluminum film foam package, to minimize the evaporation of ethanol from the soft capsule preparations. However, such special package contributes to the increase in the product volume and the production costs. Further, it has been reported that the stability of the soft capsule preparation wrapped in such special package reduces as the storage period is getting longer.

For example, Sandimun^R which is presently commercially available in the form of a liquid preparation for internal use, an injectable preparation and a soft capsule preparation has also the above-mentioned problems. Specifically, the Sandimun liquid preparation has the disadvantages that it should be diluted with milk or juice before administration and thus is difficult to provide a precise dosage. The soft capsule preparation has also a problem in that when the ethanol content in soft capsules is varied, cyclosporin dissolved in ethanol is precipitated out to decrease the bioavailability thereof. In order to avoid such problem Sandimun preparation should be wrapped in a special packing material which results in the increase of the product volume and the production costs.

In order to solve the above-mentioned disadvantages of the prior art British Patent Publication No. 2222770A proposes a preparation containing cyclosporin as an active ingredient and particularly in the form of a microemulsion or a microemulsion preconcentrate. The composition of this patent includes (1) a hydrophilic phase, (2) a hydro-

phobic phase and (3) a surfactant. In this patent, a method of formulating the composition into a hard gelatin capsule preparation is also described. However, since the composition to be filled in the hard gelatin capsule is in the liquid form, the capsule should be sealed by using a special technique, i.e. Quali-Seal technique.

In addition, Korean Laid-open Patent Publication No. 90-12625 discloses a cyclosporin galenic preparation comprising cyclosporin as an active ingredient, a fatty acid sugar monoester, and a diluent or a carrier. However, since the composition of this preparation is also in the liquid state such as solution or suspension, the hard gelatin capsule filled with the composition should be sealed by means of Quali-Seal technique as in British Patent Publication No 2222770. In addition, when the composition is absorbed into a carrier to prepare the tablet formulation, it has also a disadvantage that the stability of tablet preparations is bad due to a high hygroscopic property of saccharose monolaurate L-1695 as the fatty acid sugar monoester [see Pharmaceutical Research, Vol. 6, No. 11, 1989, p958, "Solid Surfactant Solutions of Active Ingredients in Sugar Esters" and International Journal of Pharmaceutics, Vol. 92, 1993, p197, "Applications of sucrose laurate, a new pharmaceutical excipient, in peroral formulations of cyclosporin A"]. According to the above-mentioned papers, the fatty acid sugar monoester such as saccharose monolaurate L-1695 has a hygroscopic property, it should be treated under the drying condition. Thus, under the condition of 70% relative humidity the dry fine powder should be subjected to the subsequent procedure within 30 minutes after its preparation. Further, the fatty acid sugar monoester is unsuitable for the preparation of any formulation by a direct compression, due to its poor fluidity. For improving the high hygroscopic property of saccharose monolaurate this patent uses an additive such as Plasdon XL,

Crosspovidone, etc., in a large amount. Thus, when the surfactant sensitive to water is used, the operation should be practiced under the condition of low humidity and the special package capable of excluding moisture is required to wrap the product. If the high hygroscopic surfactant such as saccharose monolaurate is used for preparing the powder formulation without such restricted condition, the surfactant absorbs the moisture to hydrolyse and therefore, the bioavailability of cyclosporin is lowered. Accordingly, it was practically impossible to prepare the cyclosporin powder formulation.

Meanwhile, Korean Laid-open Patent Publication No. 93-113 discloses a pharmaceutical composition containing cyclosporin as an active ingredient in a carrier medium comprising (1) 1,2-propyleneglycol, (2) a mixture of monoglyceride, diglyceride and triglyceride, and (3) a surfactant. However, this composition is substantially a microemulsion preconcentrate and therefore, has the same disadvantages as in British Patent Publication No. 2222770A. As other patent publications relating to the cyclosporin composition, Korean Patent Publication No. 93-6430 discloses a method for solubilizing a sparingly soluble drug with liposome. However, this method is difficult to use in the industrial scale for mass production. In addition, since according to this method the phospholipid is used in an amount of 20 to 40 times the drug, the volume of a unit dosage form is too large and therefore, this method cannot be practically used for the preparation of cyclosporin formulations in the industry.

DISCLOSURE OF INVENTION

Thus, the present inventors have considered that the powder formulation of cyclosporin will provide the more increased stability and bioavailability of cyclosporin in

comparison with the cyclosporin liquid formulation and therefore extensively studied to develop a method for preparing cyclosporin preparation in the form of a powder formulation using various surfactants and carriers. As a
5 result thereof, we have identified that cyclosporin can be prepared in the form of a stable powder composition using a certain surfactant and carrier components and thus completed the present invention.

10 Accordingly, it is an object of the present invention to provide a cyclosporin-containing powder composition which comprises (1) cyclosporin as an active ingredient, (2) a non-ionic hydrophilic surfactant and (3) a porous carrier.

15 Further, it is another object of the present invention to provide a method for preparing a cyclosporin-containing powder composition which comprises dissolving cyclosporin and a non-ionic hydrophilic surfactant in an organic
20 solvent, absorbing the resulting solution into a porous carrier and then evaporating the organic solvent.

Since the composition of the present invention is in the form of a solid powder, it is stable and does not
25 require a special manufacturing technique when it is formulated. In addition, since the powder composition of the present invention does not contain any organic solvent, the necessity of a special package is excluded. Furthermore, the composition of the present invention
30 provides an improved bioavailability of cyclosporin, which results in decrease of a single dosage, and therefore, can contribute to the alleviation of the side effects associated with cyclosporin.

BRIEF DESCRIPTION OF DRAWINGS

For a thorough understanding of the nature and objects of the invention, reference should be had to the following detailed description taken in connection with the accompanying drawing in which:

Figure 1 is a graph showing the change in blood concentration over time after the composition according to the present invention (composition I: $\blacksquare - \blacksquare$) and a commercially available cyclosporin preparation (composition II: $\square - \square$) are orally administered.

BEST MODE FOR CARRYING OUT THE INVENTION

In one aspect, the present invention relates to a cyclosporin-containing powder composition which comprises (1) cyclosporin as an active ingredient, (2) a non-ionic hydrophilic surfactant and (3) a porous carrier.

In another aspect, the present invention relates to a method for preparing a cyclosporin-containing powder composition which comprises dissolving cyclosporin and a non-ionic hydrophilic surfactant in an organic solvent, absorbing the resulting solution into a porous carrier and then evaporating the organic solvent to obtain the cyclosporin-containing powder composition in a white solid state.

Cyclosporin which is used as an active ingredient in the powder composition of the present invention is a cyclic peptide compound having useful immunosuppressive activity and antiinflammatory activity as described above.

Although cyclosporin A, B, C, D and G can be used as the cyclosporin component in the present invention, cyclosporin A is the most preferred one since its clinical effect-

tiveness and pharmacological properties are well established in the art.

The non-ionic hydrophilic surfactant which is used as the second essential component in the powder composition according to the present invention can include, for example, the following components:

1. Polyethyleneglycol mono- and di-fatty acid ester, for example, polyethyleneglycol dicaprylate, polyethyleneglycol dilaurate, polyethyleneglycol hydroxystearate, polyethyleneglycol isostearate, polyethyleneglycol laurate, polyethyleneglycol ricinolate, polyethyleneglycol stearate, and the like, and more preferably polyethyleneglycol hydroxystearate which is commercially available as Solutol^R HS15 (hydrogenation value=90-110, saponification value=53-63, acid value=maximum 1, water content=maximum 0.5%) and propyleneglycol capryl-capric acid diester which is commercially available as Myglyol^R 840 (fatty acid content=C₆ maximum approximately 3%, C₈ approximately 65-80%, C₁₀ approximately 15-30%, C₁₂ maximum 3%, acid value=maximum 0.1, iodine value=approximately 320-340).
2. Reaction product of natural or hydrogenated vegetable oil, or polyoxyethylene glycolated natural or hydrogenated vegetable oil and preferably a product which is commercially available as Cremophor^R. The specific kinds of such Cremophor product include Cremophor RH40 (saponification value=approximately 50-60, acid value=maximum 1, iodine value=maximum 1, water content=maximum 2%, n_D^{60} =approximately 1.453-1.457, HLB=approximately 14-16), Cremophor RH60 (saponification value=approximately 40-50, acid value=maximum 1, iodine value=maximum 1, water content=approximately 4.5-5.5%, n_D^{50} =approximately 1.453 -1.457, HLB=approximately 15-17) and Cremophor EL (molecular

weight= approximately 1630 (measured by a steam osmometer), saponification value= approximately 65-70, acid value= approximately 2, iodine value= approximately 28-32, n_D^{25} = approximately 1.471). For this purpose,
5 another suitable component is various products which are commercially available as Nikkol^R, preferably Nikkol HCL-60 (acid value= approximately 0.3, saponification value= approximately 47.4, hydroxylation value= approximately 42.5, pH (5%) = approximately
10 4.6, color APHA= about 40, melting point= about 36.0°C, freezing point = about 32.4°C, water content= approximately 0.03%).

3. Polyoxyethylene-sorbitan-fatty acid esters. This
15 component is commercially available under the trade mark Tween^R of which the specific example includes Tween 20 [polyoxyethylene(20) sorbitan monolaurate], Tween 40 [polyoxyethylene(20) sorbitan monopalmitate], Tween 60 [polyoxyethylene(20) sorbitan monostearate],
20 Tween 80 [polyoxyethylene(20) sorbitan monooleate], Tween 65 [polyoxyethylene(20) sorbitan tristearate], Tween 85 [polyoxyethylene(20) sorbitan trioleate], Tween 21 [polyoxyethylene(4) sorbitan monolaurate], Tween 61 [polyoxyethylene(4) sorbitan stearate], Tween
25 81 [polyoxyethylene(5) sorbitan monooleate], and the like.

4. Polyoxyethylene-polyoxypropylene copolymers. This
30 component is commercially available under the trade mark Emkalyx^R and Pluronic^R. In the composition of the present invention Pluronic F68 is more preferably used.

5. Polyoxyethylene-polyoxypropylene block copolymers.
35 This component is commercially available under the trade mark Poloxamer^R. In the composition of the present invention Poloxamer 188 is more preferably

used.

6. Polyoxyethylene fatty acid esters. This component is commercially available under the trade mark Cetiol^R HE and Myri^R, of which the most preferable one is Myri 52 (D²⁵= approximately 1.1, melting point= approximately 40-44°C, HLB= approximately 16.9, acid value= approximately 0-1, saponification value= approximately 25-35).

The porous carrier which is used as the third essential component in the composition of the present invention provides an advantage that a porosity of the carrier contributes to the increase in the surface area to increase the solubility. In addition, the porous carrier used in the present invention should satisfy the pharmaceutically acceptable general conditions that it does not cause any internal toxicity, has no antigenicity and is not accumulated in the body. Further, the carrier according to the present invention should have a stability to the impact during the processing procedures, a low solubility in organic solvent and an applicability to a human being, and should be suited for the condition depending on the desired administration routes.

Specific example of the porous carrier suitable for the present invention includes a water-soluble carrier such as sorbitol, sodium chloride, mannitol, lactose and the like. Since such carrier is completely dissolved within the human body, it contributes to the increase in bioavailability of cyclosporin. The most preferable one which can be used in the present invention is sorbitol.

In the composition of the present invention a water-insoluble carrier can also be used as the porous carrier. Specific example of the water-insoluble porous carrier

includes micronized silicon dioxide or its alkylated compound, for example, the products commercially available under the trade mark Syllysia^R and Aerosil^R. The most preferable one which can be used in the present invention is Syllysia 350 [average particle diameter=1.8 μ m, loss on drying (950°C, 2 hours)=5%, pH(5% slurry)= approximately 7.5, whiteness degree=96, surface area=300(m²/g), oil absorption=310(ml/100g), cavity volume=90(ml/5g)].

In the composition of the present invention the non-ionic hydrophilic surfactant is used in the weight ratio of 1:1-20, preferably 1:2-15 and particularly preferably 1:3-10, with respect to cyclosporin as an active ingredient. In addition, the porous carrier is used in the weight ratio of 1:1-20, preferably 1:2-15 and particularly preferably 1:2-10, with respect to cyclosporin.

In the method for preparation of the composition according to the present invention, first cyclosporin and an non-ionic hydrophilic surfactant are dissolved in an organic solvent; the resulting solution is absorbed into a porous carrier; and the organic solvent is evaporated under reduced pressure from the absorbed carrier to obtain the solid product which can be then sieved to obtain a powder having the desired uniform size.

As the organic solvent in the method according to the present invention any low boiling solvent in which cyclosporin and the non-ionic hydrophilic surfactant can be dissolved can be used. Specific example of the solvent which can be used in the present invention includes methanol, ethanol, acetone, ether, chloroform, etc., of which any one solvent can be used alone or, if necessary, a mixture of two or more can also be used.

Although the cyclosporin-containing powder composition prepared according to the present invention can be used as

it is prepared, it can also be used in the form of pharmaceutical preparation, for example, a solid formulation such as granule, tablet, hard capsule and the like, which is prepared using pharmaceutically acceptable conventional additives according to a conventional pharmaceutical method. In addition, the cyclosporin-containing powder composition of the present invention can be formulated in the form of a slow-released preparation. All of such cyclosporin preparations are included within the scope of the present invention.

The additive which can be used for this purpose includes a binder, a disintegrant, a lubricant, an excipient, a flavoring agent, a coloring agent, a taste corrective agent, and the like, which can be conventionally used in preparing the solid preparations.

The cyclosporin-containing powder composition, comprising the above-mentioned components, according to the present invention has advantages that since the composition is prepared in the form of a solid powder, it does not require any special condition and technique for their formulation in contrast to the prior preparations requiring a special technique such as Quali-Seal in their formulation, and further the necessity of a special package is excluded because it does not contain any organic solvent. In addition, in the composition of the present invention the content of cyclosporin is stably maintained and therefore, the bioavailability of cyclosporin is increased in comparison with the prior art preparations. Accordingly, the composition of the present invention can allow to decrease the single dosage of cyclosporin and thus to reduce the occurrence of side effects. This can be a significant improvement since cyclosporin may cause a serious nephrotoxicity.

The present invention will be more specifically illus-

trated by the following examples. However, it should be understood that the present invention is not limited by these examples in any manner.

5

EXAMPLE 1 (Powder)

	Cyclosporin	100mg
	Solutol HS15	500mg
10	Sorbitol	500mg
		<hr/>
		Total 1,100mg

15 500mg of Solutol HS15 was dissolved in 1000mg of ethanol and then 100mg of cyclosporin was dissolved therein. The resulting solution was mixed with 500mg of sorbitol having a particle size of 300 to 500 μ m and the mixture was dried at 40°C under reduced pressure to evaporate ethanol. 1100mg of the obtained white solid was
20 sieved to obtain the powder having a uniform particle size of 300 to 500 μ m, which corresponds to the single dosage for 100mg of cyclosporin.

25

EXAMPLE 2 (Powder)

	Cyclosporin	100mg
	Cremophor RH40	600mg
30	Sylsia 350	300mg
		<hr/>
		Total 1,000mg

35 The above-mentioned components were treated according to the same procedure as Example 1 to obtain a white powder preparation.

EXAMPLE 3 (Granule)

	Cyclosporin	100mg
	Myglyol 840	450mg
5	Sorbitol	500mg
	Hydroxypropylmethylcellulose	30mg
		<hr/>
	Total	1,080mg

10

Cyclosporin, Myglyol 840 and sorbitol were treated according to the same procedure as Example 1 to obtain a white powder which was then mixed with a solution of 30mg of hydroxypropylmethylcellulose dissolved in 300mg of
15 distilled water to obtain the granule preparation.

EXAMPLE 4 (Granule)

20	Cyclosporin	100mg
	Cetiol HE	450mg
	Sylsia 350	300mg
	Methylcellulose	30mg
		<hr/>
25	Total	880mg

The above-mentioned components were treated according to the same procedure as Example 3 to obtain the granule
30 preparation.

EXAMPLE 5 (Tablet)

35	Cyclosporin	100mg
	Solutol HS15	500mg
	Sylsia 350	300mg

15

Corn starch	70mg
Magnesium stearate	7mg

Total 977mg

5

Cyclosporin, Solutol HS15 and Sylysia 350 were treated according to the same procedure as Example 1 to obtain the powder. Separately, 70mg of corn starch was added to 10 1000mg of distilled water and then heated to prepare the binder solution. The powder obtained above was mixed with the binder solution to prepare the granule which was then dried. The prepared granule was mixed with 7mg of magnesium stearate and then the mixture was compressed to 15 obtain a tablet containing 50mg of cyclosporin per tablet.

EXAMPLE 6 (Tablet)

20	Cyclosporin	50mg
	Tween 80	50mg
	Myri 52	300mg
	Sorbitol	250mg
	Hydroxypropylmethylcellulose	90mg
25	Magnesium stearate	18mg
	Aerosil 200	9mg

Total 767mg

30

Cyclosporin, Tween 80, Myri 52 and sorbitol were treated according to the same procedure as Example 1 to obtain the powder which was then mixed with a solution of hydroxypropylmethylcellulose dissolved in 250mg of the 35 mixture of methanol and methylene chloride to prepare the granule. The prepared granule was dried and mixed with 18mg of magnesium stearate and 9mg of Aerosil 200 and then

16

the mixture was compressed to obtain a tablet containing 50mg of cyclosporin per tablet.

5 EXAMPLE 7 (Tablet)

	Cyclosporin	100mg
	Cremophor RH40	600mg
	Sorbitol	350mg
10	Hydroxypropylmethylcellulose	75mg
	Magnesium stearate	30mg

Total 1,155mg

15

The above-mentioned components were treated according to the same procedure as Example 6 to obtain the tablet preparation.

20

EXAMPLE 8 (Hard gelatin capsule)

	Cyclosporin	50mg
	Pluronic F68	200mg
25	Myglyol 840	100mg
	Sylsia 350	250mg
	Methylcellulose	25mg

Total 625mg

30

The above-mentioned components were treated according to the same procedure as Example 4 to obtain the granule which was then filled in a hard gelatin capsule to obtain
35 the capsule preparation.

17

EXAMPLE 9 (Hard gelatin capsule)

	Cyclosporin	50mg
	Poloxamer 188	300mg
5	Sorbitol	350mg
		<hr/>
	Total	700mg

10 The above-mentioned components were treated according to the same procedure as Example 1 to obtain the powder which was then filled in a hard gelatin capsule to obtain the capsule preparation.

15

EXAMPLE 10 (Hard gelatin capsule)

	Cyclosporin	50mg
	Solutol HS15	150mg
20	Cremophor RH60	200mg
	Sorbitol	350mg
	Aerosil 200	17mg
		<hr/>
	Total	767mg

25

Cyclosporin, Solutol HS15, Cremophor RH60 and sorbitol were treated according to the same procedure as Example 1 to obtain the powder which was then mixed with Aerosil 200. The mixture was filled in a hard gelatin capsule to obtain the capsule preparation.

30

TEST EXAMPLE

35

Comparative test for bioavailability of the composition of the present invention and the commercial product in dogs

The bioavailability of the composition according to the present invention was identified from the following experiment.

5 a). Test compositions

Composition I (composition of the present invention):

	Cyclosporin	25mg
10	Solutol HS15	250mg
	Sylsia 50	125mg
	Collidon CL	8mg
		<hr/>
	Total	408mg

15

Composition II: SANDIMUN^R 25mg Soft capsule
(Lot No. 114MFD1293)

b) Test procedure

20

In this experiment, 6 male dogs weighing 11.0-15.0kg were used as the test animal. The test animal was fasted from 18 hours before administration of the test compositions, except that they are allowed to drink water. The test compositions (4 capsules) corresponding to 100mg of cyclosporin per dog was orally administered by compulsion to the test animal and then 50ml of water was administered to each test animal. After 4 hours from administration of the test compositions the foodstuffs were administered to the test animal. In this test the test animals were divided into two groups in which each group consists of 1 dogs, and the experiment was practiced according to the cross-over test method.

35

Blood was collected from a juglar vein in an amount of 2ml each time before administration of the test compositions and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10 and 12.

hours after administration of the test compositions, and then stored at -18°C . According to a method disclosed in the literature (Pharmaceutical Research, Vol. 8, No. 4, 1991, p518), the blood was pretreated with an organic solvent and then analyzed by means of HPLC [solvent : CH_3CN /pH 2.5 buffer solution/methanol=50/45/5, column : Lichrosorb RP-8 ($5\mu\text{m}$), wavelength : 215nm, temperature : 70°C , flow rate : 2.0ml/min.].

10 C) Result

As the result of administration of two test compositions to 6 dogs according to the above-mentioned test procedure, AUC (ng·hr/ml) and blood concentration of cyclosporin in each group were described in the following Tables 1 and 2 and also depicted in Figure 1.

20

25

30

35

Table 1. AUC (ng·hr/ml) after oral administration of the composition of the present invention and the commercial product

	Composition I	Composition II
A	3305.05	3016.43
B	3487.46	2910.20
C	2979.27	1614.13
D	6948.64	3244.72
E	3448.35	2354.94
F	6358.45	3166.61
Average	4421.20	2717.84

Table 2: Blood concentration (ng/ml) of cyclosporin after oral administration of the composition of the present invention and the commercial product.

5

	Time (hr)	Composition I	Composition II
10	0.0	0.00	0.00
	1.0	546.96	629.12
	1.5	617.35	759.46
15	2.0	1013.82	399.60
	2.5	668.41	369.04
20	3.0	592.74	254.22
	4.0	421.03	228.50
	5.0	317.38	167.87
25	6.0	275.43	167.63
	8.0	187.99	148.06
30	10.0	185.46	124.81
	12.0	130.73	97.75

35

As can be seen from the result shown in the above tables and figure, the composition of the present invention shows an increase in the bioavailability by about 62% in comparison with the composition II as the commercial product. In addition, in view of the fact that the blood concentration of cyclosporin is maintained at 250ng/ml or more by administration of the composition of the present invention, the duration of an effective blood concentration of about 250ng/ml following to administration of the composition of the present invention is about two times that of the commercial product.

Although this invention has been described in its preferred form with a certain degree of particularity, it is appreciated by those skilled in the art that the present disclosure of the preferred form has been made only by way of example and that numerous changes in the details of the construction, combination and arrangement of parts may be resorted to without departing from the spirit and scope of the invention.

25

30

35

WHAT IS CLAIMED IS :

1. A cyclosporin-containing powder composition which
5 .. comprises (1) cyclosporin, (2) a non-ionic hydrophilic
surfactant and (2) a porous carrier.
2. The cyclosporin-containing powder composition of claim
1, characterized in that said cyclosporin is cyclospo-
10 rin A.
3. The cyclosporin-containing powder composition of claim
1, characterized in that the non-ionic hydrophilic
15 surfactant is selected from the group consisting of:
polyethyleneglycol mono- and di-fatty acid esters, the
reaction products of natural or hydrogenated vegetable
oil, polyoxyethyleneglycolated natural or hydrogenated
vegetable oils, polyoxyethylene-sorbitan-fatty acid
20 esters, polyoxyethylene-polyoxypropylene copolymers,
polyoxyethylene-polyoxypropylene block copolymers and
polyoxyethylene fatty acid esters.
4. The cyclosporin-containing powder composition of claim
3, characterized in that the non-ionic hydrophilic
25 surfactant is polyethyleneglycol mono- or di-fatty
acid esters.
5. The cyclosporin-containing powder composition of claim
4, characterized in that the non-ionic hydrophilic
30 surfactant is polyethyleneglycol hydroxystearate
(Solutol HS 15).
6. The cyclosporin-containing powder composition of claim
1, characterized in that the porous carrier is a
35 water-soluble carrier selected from the group consist-
ing of: sorbitol, sodium chloride, mannitol and lac-
tose.

7. The cyclosporin-containing powder composition of claim 6, characterized in that the carrier is sorbitol.
8. The cyclosporin-containing powder composition of claim 5 1, characterized in that the porous carrier is a water-insoluble carrier selected from the group consisting of: micronized silicon dioxide and its alkylated compounds.
9. The cyclosporin-containing powder composition of claim 8, characterized in that the carrier is Sylysia.
10. The cyclosporin-containing powder composition of claim 1, characterized in that the ratio of cyclosporin to 15 non-ionic hydrophilic surfactant is 1:1-20 (w/w).
11. The cyclosporin-containing powder composition of claim 10, characterized in that the ratio of cyclosporin to non-ionic hydrophilic surfactant is 1:3-10 (w/w).
12. The cyclosporin-containing powder composition of claim 1, characterized in that the ratio of cyclosporin to porous carrier is 1:1-20 (w/w).
13. The cyclosporin-containing powder composition of claim 12, characterized in that the ratio of cyclosporin to porous carrier is 1:2-10 (w/w).
14. The cyclosporin-containing powder composition of claim 1, characterized in that the composition is formulated 30 into a granule, tablet or hard gelatin capsule.
15. A method for preparing the cyclosporin-containing powder composition according to any one of claims 1 to 35 14, characterized in that
 - (a) cyclosporin and a non-ionic hydrophilic surfact-

25

ant are dissolved in an organic solvent,

(b) a porous carrier is added to the resulting solution, and

(c) the organic solvent is evaporated from the mixture.

16. The method of claim 15, characterized in that the organic solvent is one or more solvents selected from the group consisting of: methanol, ethanol, acetone, ether and chloroform.

AMENDED CLAIMS

[received by the International Bureau on 7 March 1995 (07.03.95);
original claims 1,8,12,13 and 15 amended; original claims 6,7 cancelled
remaining claims unchanged (3 pages)]

51. A cyclosporin-containing powder composition which comprises (1) cyclosporin, (2) a non-ionic hydrophilic surfactant and (3) a porous, water-insoluble carrier.
2. The cyclosporin-containing powder composition of claim 1, characterized in that said cyclosporin is cyclosporin A.
3. The cyclosporin-containing powder composition of claim 1, characterized in that the non-ionic hydrophilic surfactant is selected from the group consisting of: polyethyleneglycol mono- and di-fatty acid esters, the reaction products of natural or hydrogenated vegetable oil, polyoxyethyleneglycolated natural or hydrogenated vegetable oils, polyoxyethylene-sorbitan-fatty acid esters, polyoxyethylene-polyoxypropylene copolymers, polyoxyethylene-polyoxypropylene block copolymers and polyoxyethylene fatty acid esters.
4. The cyclosporin-containing powder composition of claim 3, characterized in that the non-ionic hydrophilic surfactant is polyethyleneglycol mono- or di-fatty acid esters.
5. The cyclosporin-containing powder composition of claim 4, characterized in that the non-ionic hydrophilic surfactant is polyethyleneglycol hydroxystearate (Solutol HS 15).
8. The cyclosporin-containing powder composition of claim 1, characterized in that the water-insoluble carrier is selected from the group consisting of: micronized silicon dioxide and its alkylated compounds.

9. The cyclosporin-containing powder composition of claim 8, characterized in that the carrier is Sylysia.
10. The cyclosporin-containing powder composition of claim 1, characterized in that the ratio of cyclosporin to non-ionic hydrophilic surfactant is 1:1-20 (W/W).
11. The cyclosporin-containing powder composition of claim 10, characterized in that the ratio of cyclosporin to non-ionic hydrophilic surfactant is 1:3-10 (W/W).
12. The cyclosporin-containing powder composition of claim 1, characterized in that the ratio of cyclosporin to porous water-insoluble carrier is 1:1-20 (W/W).
13. The cyclosporin-containing powder composition of claim 12, characterized in that the ratio of cyclosporin to porous water-insoluble carrier is 1:2-10 (W/W).
14. The cyclosporin-containing powder composition of claim 1, characterized in that the composition is formulated into a granule, tablet or hard gelatin capsule.
15. A method for preparing the cyclosporin-containing powder composition according to any one of claims 1-5, 8-14, characterized in that
- (a) cyclosporin and a non-ionic hydrophilic surfactant are dissolved in an organic solvent,
 - (b) a porous water-insoluble carrier is added to the resulting solution, and
 - (c) the organic solvent is evaporated from the mixture.
16. The method of claim 15, characterized in that the organic solvent is one or more solvents selected from

the group consisting of: methanol, ethanol, acetone,
ether and chloroform.

5

10

15

20


25

30

35

1/1

FIG. 1



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 94/00125

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: A 61 K 38/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Derwent - WPIL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, A, 01 038 029 (TAKADA) 08 February 1989 (08.02.89), abstract. -----	1-3, 6, 7, 15, 16

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 December 1994 (13.12.94)

Date of mailing of the international search report

11 January 1995 (11.01.95)

Name and mailing address of the ISA/ AT
AUSTRIAN PATENT OFFICE

Authorized officer

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 94/00125

In Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
JP A2 1038029	08-02-89	keine - none - rien	